Amended Report of Foreign Issuer (6-k/a)
27 Março 2019 - 7:10AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 6-K/A
Report of Foreign
Private Issuer
Pursuant to Rule
13a-16 or 15d-16
of the Securities
Exchange Act of 1934
For the month of March
2019
PRANA
BIOTECHNOLOGY LIMITED
(Name of Registrant)
Level 3, 460 Bourke
Street, Melbourne, VIC 3000, Australia
(Address of principal
executive offices)
Indicate by check
mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Indicate by check
mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
¨
No
x
If "Yes"
is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ____________
This Form 6-K/A is being incorporated by
reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-220886) and Form S-8 (File No. 333-228671).
PRANA BIOTECHNOLOGY LIMITED
(a development stage enterprise)
EXPLANATORY NOTE:
This 6-K/A is being filed solely to
amend the legend at the bottom of the cover page of the initial 6-K filed February 28, 2019 to indicate that it is being incorporated
by reference into the Registrant’s Registration Statements.
The following exhibits are submitted:
|
99.1
|
Condensed Consolidated Financial Statements of Prana Biotechnology Limited and Subsidiaries (a development stage enterprise) as of December 31, 2018
|
|
99.2
|
Operating and Financial Review and Prospects for the Six Months ended December 31, 2018
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Prana Biotechnology Limited
|
|
|
|
|
|
/s/ Geoffrey P. Kempler
|
|
By: Geoffrey P. Kempler
|
|
Executive Chairman
|
Date:
March 27, 2019
Alterity Therapeutics (PK) (USOTC:PRNAF)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Alterity Therapeutics (PK) (USOTC:PRNAF)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024